Literature DB >> 17011379

Oxybutynin in detrusor overactivity.

Ananias Diokno1, Michael Ingber.   

Abstract

Oxybutynin has been used for the management of detrusor overactivity for over 30 years and has withstood medical scrutiny and the test of time throughout the world. Although several agents in the class of bladder relaxants have only recently been studied, oxybutynin's effectiveness in reducing urinary frequency and urge urinary incontinence is unquestioned in the medical literature. Oxybutynin is extremely safe and effective in almost every population including children, the elderly, and those who have neurogenic bladder. With more preparations available and more dosing flexibility than any other anticholinergic medication on the market, oxybutynin remains the "gold standard" for first-line therapy for patients who have detrusor overactivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011379     DOI: 10.1016/j.ucl.2006.06.003

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  6 in total

1.  Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia.

Authors:  Minki Baek; Jung Yoon Kang; Jeongyun Jeong; Dae Kyung Kim; Kwang Myung Kim
Journal:  Int Urol Nephrol       Date:  2013-03-31       Impact factor: 2.370

Review 2.  Diagnosis and therapy for neurogenic bladder dysfunctions in multiple sclerosis patients.

Authors:  Giulio Del Popolo; Giovanni Panariello; Francesca Del Corso; Giuseppe De Scisciolo; Giuseppe Lombardi
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

3.  Characteristics of neurogenic voiding dysfunction in cerebellar stroke: a cross-sectional, retrospective video urodynamic study.

Authors:  Yu-Cheng Chou; Yuan-Hong Jiang; Tomor Harnod; Hann-Chorng Kuo
Journal:  Cerebellum       Date:  2013-10       Impact factor: 3.847

4.  Shifting to 4 × 1 intermittent catheterization without an early follow-up urodynamic study is possible in most patients with subacute spinal cord injury.

Authors:  Murat Ersöz; Engin Koyuncu; Müfit Akyüz; Neşe Özgirgin
Journal:  J Spinal Cord Med       Date:  2016-04-01       Impact factor: 1.985

5.  Oxybutynin-Induced Hyperthermia in a Patient With Parkinson's Disease.

Authors:  Saad Ahmad; Jonathan Vincent M Reyes; Joseph Lieber
Journal:  Cureus       Date:  2021-04-26

6.  Oxybutynin extended release for the management of overactive bladder: a clinical review.

Authors:  A M Arisco; E K Brantly; S R Kraus
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.